Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia in the treatment of advanced ovarian cancer

Zhang,Ting; Pan,Qiong; Xiao,Songshu; Li,Lijie; Xue,Min

doi:10.3892/ol.2016.4414

Docetaxel combined with intraperitoneal hyperthermic perfusion chemotherapy and hyperthermia in the treatment of advanced ovarian cancer

Authors:
- Ting Zhang
- Qiong Pan
- Songshu Xiao
- Lijie Li
- Min Xue
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China
Published online on: April 5, 2016 https://doi.org/10.3892/ol.2016.4414
Pages: 3287-3292
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is a clinical type of gynecological malignant tumor with poor prognosis and a high mortality rate. At present, the primary treatment method used is surgery, with chemotherapy as an ajdunctive therapy. Thus, new short-term treatments should be identified. The aim of the present study was to investigate the short-term curative effects and safety of docetaxel combined with intraperitoneal cisplatin chemotherapy and hyperthermia treatment of advanced ovarian cancer. A total of 112 cases of advanced (stage III‑IV) ovarian cancer patients confirmed by clinical diagnosis between October 2014 and December 2015 were included in the study. The patients were randomly divided into the study and control groups (n=56 cases). The control group was treated with docetaxel and intraperitoneal cisplatin hyperthermic perfusion chemotherapy, while the study group was treated with docetaxel venous chemotherapy and intraperitoneal cisplatin cyclical hyperthermic perfusion chemotherapy with BR-TRG-1 body cavity hyperthermic perfusion treatment system. Clinical treatment results for short-term curative effects and adverse reactions were compared and analyzed 8 weeks after treatment. The total effective rate of the study and control groups were 87.5 and 62.5%, respectively, and the difference was statistically significant (P<0.05). The controlled rate of ascites, remission rate of tumor and descent rate of CA125 of patients in the study group were better than patients in the control group (P<0.05). The rate of adverse reactions of patients in the study group was 39.3%, and the grade of toxicity was from I to II, while the rate of adverse reactions of patients in the control group was 55.4%, and the grade of toxicity was from II to III. The difference between the two groups was statistically significant (P<0.05). In conclusion, applying the combination of docetaxel, intraperitoneal cisplatin hyperthermic perfusion chemotherapy and hyperthermia to treat advanced ovarian cancer can improve the curative effects with little toxicity; thus, it is worthy of promotion and application.

View Figures

View References

1	Miyashiro I, Furukawa H, Sasako M, Yamamoto S, Nashimoto A, Nakajima T, Kinoshita T, Kobayashi O and Arai K: Gastric Cancer Surgical Study Group in the Japan Clinical Oncology Group: Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2. Gastric Cancer. 14:212–218. 2011. View Article : Google Scholar : PubMed/NCBI
2	Emoto S, Kitayama J, Ishigami H, Yamaguchi H and Watanabe T: Clinical significance of cytological status of peritoneal lavage fluid during intraperitoneal chemotherapy for gastric cancer with overt peritoneal dissemination. Ann Surg Oncol. 22:780–786. 2015. View Article : Google Scholar : PubMed/NCBI
3	Chua TC, Morris DL, Saxena A, Esquivel J, Liauw W, Doerfer J, Germer CT, Kerscher AG and Pelz JO: Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol. 18:1560–1567. 2011. View Article : Google Scholar : PubMed/NCBI
4	Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P and Glehen O: Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 28:63–68. 2010. View Article : Google Scholar : PubMed/NCBI
5	Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H, et al: Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 21:67–70. 2010. View Article : Google Scholar : PubMed/NCBI
6	Elias D, Glehen O, Pocard M, Quenet F, Goéré D, Arvieux C, Rat P and Gilly F: Association Française de Chirurgie: A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg. 251:896–901. 2010. View Article : Google Scholar : PubMed/NCBI
7	Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y and Li Y: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 18:1575–1581. 2011. View Article : Google Scholar : PubMed/NCBI
8	Kapala M, Meterissian S and Schricker T: Neuraxial anesthesia and intraoperative bilevel positive airway pressure in a patient with severe chronic obstructive pulmonary disease and obstructive sleep apnea undergoing elective sigmoid resection. Reg Anesth Pain Med. 34:69–71. 2009. View Article : Google Scholar : PubMed/NCBI
9	Chua TC, Morris DL and Esquivel J: Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 17:1330–1336. 2010. View Article : Google Scholar : PubMed/NCBI
10	Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H and Watanabe T: A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer. 119:3354–3358. 2013. View Article : Google Scholar : PubMed/NCBI
11	Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL and Zeh HJ III: Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 116:3756–3762. 2010. View Article : Google Scholar : PubMed/NCBI
12	Diéras V, Guastalla JP, Ferrero JM, Curé H, Weber B, Winckel P, Lortholary A, Mayer F, Paraiso D, Magherini E, et al: A multicenter phase II study of cisplatin and docetaxel (Taxotere) in the first-line treatment of advanced ovarian cancer: A GINECO study. Cancer Chemother Pharmacol. 53:489–495. 2004. View Article : Google Scholar : PubMed/NCBI
13	Kitayama J, Ishigami H, Yamaguchi H and Watanabe T: Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) combined with oral tegafur/gimeracil/oteracil potassium (S-1) for gastric cancer with peritoneal metastasis. Eur J Surg Oncol. 40:S342014. View Article : Google Scholar
14	Lee AW, Tyrer JP, Doherty JA, Stram DA, Kupryjanczyk J, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Spiewankiewicz B, Myers EJ, Chenevix-Trench G, et al: Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group: Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecol Oncol. 136:542–548. 2015. View Article : Google Scholar : PubMed/NCBI
15	Che YL, Luo SJ, Li G, Cheng M, Gao YM, Li XM, Dai JM, He H, Wang J, Peng HJ, et al: The C3G/Rap1 pathway promotes secretion of MMP-2 and MMP-9 and is involved in serous ovarian cancer metastasis. Cancer Lett. 359:241–249. 2015. View Article : Google Scholar : PubMed/NCBI
16	Hung SW, Marrache S, Cummins S, Bhutia YD, Mody H, Hooks SB, Dhar S and Govindarajan R: Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach. Cancer Lett. 359:233–240. 2015. View Article : Google Scholar : PubMed/NCBI
17	Wang J, Yang H, Li W, Xu H, Yang X and Gan L: Thioredoxin 1 upregulates FOXO1 transcriptional activity in drug resistance in ovarian cancer cells. Biochim Biophys Acta. 1852:395–405. 2015. View Article : Google Scholar : PubMed/NCBI
18	Bakrin N, Classe JM, Pomel C, Gouy S, Chene G and Glehen O: Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. J Visc Surg. 151:347–353. 2014. View Article : Google Scholar : PubMed/NCBI
19	Helm CW: Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. Surg Oncol Clin N Am. 21:645–663. 2012. View Article : Google Scholar : PubMed/NCBI
20	Parson EN, Lentz S, Russell G, Shen P, Levine EA and Stewart JH IV: Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms. Am J Surg. 202:481–486. 2011. View Article : Google Scholar : PubMed/NCBI
21	Ohashi N, Jinno S, Kobayashi D, Tanaka C, Yamada S, Fujii T, Nomoto S, Fujiwara M, Takeda S and Kodera Y: Intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Nihon Shokaki Geka Gakkai Zasshi. 45:1137–1143. 2012.(In Japanese). View Article : Google Scholar
22	Gupta D and Lis CG: Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature. J Ovarian Res. 2:132009. View Article : Google Scholar : PubMed/NCBI